Neumora
Neumora’s Navacaprant Fails to Meet Expectations in First Phase 3 Trial for Major Depressive Disorder
Neumora Therapeutics, Navacaprant, Major Depressive Disorder, Phase 3 Trial, KOASTAL-1 Study
Neumora’s Schizophrenia Drug Study Halted by FDA Due to Preclinical Safety Signals
Neumora Therapeutics, Schizophrenia drug study, NMRA-266, Preclinical safety signals, Convulsions in rabbits, Clinical hold, Phase I trial
Neumora Therapeutics’ Schizophrenia Drug NMRA-266 Faces FDA Hold Over Convulsions in Rabbits
Neumora, United States Food and Drug Administration, NMRA-266, Seizures, Schizophrenia